| Patients with protective antibody levels at 1.5 years of follow-up (n= 132) | Patients without protective antibody levels at 1.5 years of follow-up (n= 170) | P value |
---|---|---|---|
Age (years); mean (SD) (range) | 51.7 (13) (24-79) | 60.1 (11) (30-85) | P < 0.001 a |
Patient age ≥65 years (%) | 16% | 37% | P < 0.001 b |
Gender (female %) | 58% | 72% | P = 0.01 b |
Disease duration (years); mean (SD) (range) | 13.8 (10) (0-45) | 16.7 (11) (0-46) | P = 0.039 a |
DAS at vaccination; mean (SD) (range) | 3.0 (1.3) (0-5.6) | 3.5 (1) (0-6.4) | P = 0.001 a |
HAQ at vaccination; mean (SD) (range) | 0.6 (0.5) (0-2) | 0.9 (0.7) (0-3) | P < 0.001 a |
RA (yes, %) | 38/62 | 66/34 | P < 0.001 b |
Ongoing MTX (yes, %) | 44% | 61% | P < 0.001 b |
Ongoing anti-TNF treatment (yes, %) | 60% | 72% | P = 0.029 b |
Positive antibody response for 6B and 23F at 4 to 6 weeks of follow-up (yes, %) | 37.1% | 25% | P = 0.027 b |
Protective antibody levels for both 6B and 23F serotypes at vaccination (%) | 72% | 20.6% | P < 0.001 b |